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Natrium iodide symporter (NIS) is an iodide co-transporter, which plays a pivotal role in radioiodine uptake in breast cancer cells. The 
level of NIS expression in breast cancer tissues was reported to be varied between studies. Adenosine triphosphate (ATP) and 
epidermal growth factor (EGF) are proliferative agents which activateextracellular signal-regulated kinase (ERK). The signaling 
pathway has been known, play an important roles in NIS expression regulation.  The aim of this study is to investigatethe effect of 
ATP, EGF and combination of those two to the NIS expression in MCF7 and SKBR3 cell lines.  
MCF7 cell line is representing the luminal type of breast cancer and SKBR3 cell line is representingthe human epidermal receptor 2 
(HER2) type.Hacat cell line, a non-cancer cell, is used as control. Cells were treated with ATP, EGF and combination of those two for 
6, 12 and 24 hours. The expression of NIS mRNAwas measured throughquantitative-reverse transcription-polymerase chain reaction 
(qRT-PCR). The NIS protein expression was confirmed by immunocytofluoresence. 
Natrium iodide symporterwas expressed in SKBR3and in Hacat cells with or without ATP and EGF treatment. However the same 
treatment did not induce NIS expression in MCF7 cells .The combination of ATPand EGF treatment for 24 hours  enhanced the level 
of NISmRNAexpression in SKBR3 cell line by 1.6 folds compared to that of untreated cells (p<0.05).It also increased NIS protein 
expression at membrane cells in SKBR3 cell line. 
The level of NIS expression is different among subtypes of breast cancer cell lines. ATP and EGF combination treatment increases 
NISmRNAand protein expression in SKBR-3cells line. 
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Introduction 
 
Natrium Iodide Symporter is a plasma membrane glycoprotein. It transports two ions of natrium (Na+) and one 
of iodide (I-) and maintained by Na+/K+ ATPase1,2.In thyroid cells, NIS  plays a pivotal role to accumulate an 
iodine. Additionally, NIS is also expressed in breast cancer tissue and has been considered as a potential target 
for radioiodine therapy. However, NIS expression in breast cancer tissues had been reported to be varied 
between studies. Furthermore, molecular mechanism of NIS expression in breast cancer remains unclear. 
Interestingly, it has been reported that NIS is highly expressed in invasive breast cancer tissues. Study by 
Tazebayet al reported that indeed there is a correlation between NIS expression and malignant transformation of 
human breast tissue3,4. 
Other than the variation of NIS expression level between molecular subtypes of breast cancer, the location of 
NIS expression is another factor that may influence the uptake of radioiodine by breast cancer cells. Natrium 
Iodide Symportersupposed to be localizedat membrane cell instead in the cytoplasm to be fully functional as 
iodine co-transporter5,6.Several agents were used to increase NIS expression in breast cancer cells. Theeffectof 
those agents had been proven could increase  radioiodine uptake  and cells susceptibility toward the treatment. 
In T47D cell line, epidermal growth factor (EGF) treatment was reported to have anincrease inNIS expression 
at membrane cell7.Another study reported that a combination of ATP with all-trans-Retinoid Acid (tRA) and 
hydrocortisone has increased NIS protein expression and cell membrane targeting in MCF7 cells8. 
 
 
In this study, we examined the effect ofEGF and ATP treatment forNIS mRNA and protein expressions in 
SKBR3 and MCF7breast cancer cell lines. MCF7 and SKBR3 cell lines are representing the luminal and  HER2 
type of breast cancer respectively9.Hacat cell line, a human keratinocyte cell lines, is used as a control. 
 
 
 Material and Methods 
 
Cell lines and culture conditions 
 
SKBR3, MCF7 and Hacat cell lines were used in this study. SKBR3was obtained from the American Type 
Culture Collection (ATCC). MCF7 and Hacat cell lines were kindly provide by Dr. Ahmad Fariedfromfaculty 
of Medicine, UniversitasPadjadjaran, Bandung-Indonesia. MCF7and Hacat cells were cultured in RPMI 1640 
medium(Sigma-Aldrich). SKBR3 was cultured in Mccoy’s 5A medium(Sigma-Aldrich). Both cell culture 
mediums were supplemented with 10% fetal bovine serum (Sigma-Aldrich), 1% Penicillin, 1% Streptomycin and 
1% amphotericin B. The cells were incubated at 37oC and supplied with 5% of carbon dioxide (CO2) until 80% 
confluence. The cells were incubated in serum-free medium overnight, and followed by treatment of EGF 
50ng/ml (Abcam #ab9697), ATP 100M (Sigma-Aldrich # 1388), anda combination of EGF and ATP, for 6, 12 
and 24 hours. The cells without any treatment were used as a control 
 
Quantitative Real-time reverse transcriptase –PCR (qRT-PCR) 
    The cells were harvested at the appropriate time pointsby trypsinized, and then followed by centrifuged at 
1000 rpm for a period of 4 minutes. The total RNA was isolated by using RNeasy mini kit (Qiagen #74106) 
following the manufacturer’s instructions. RNA was quantified using Nanodrop 2000and  5 ngof RNA was 
reverse transcribed and analyzed by one step real-time quantitative PCR using Rotor Gene Quantitect probe RT-
PCR (Qiagen # 204443) using NIS and beta actin primers.  The NIS expression fold change of treated cells to 
those untreated was analyzed using a method describe by Livak et al10. Three independent qPCR assays were 
conducted in triplicate.  
 
Immunocytofluoresence 
The cells were seeded on coverslips in  awells of a 24-wells culture plate and fixated by 4% paraformaldehyde 
for 15 minutes. This was followed by incubation with protein blocking agent fluorescein-isothiocyanate (FITC) 
for 15 minutes. The cells were rinsed twice with an ice-cold PBS and followed by an overnight incubation with 
2µg/ml rabbit polyclonal antibody anti-NIS(Abcam,#ab83816) at 4oC.The cells were rinsed three times with 
PBS and incubated at room temperature with Goatanti-Rabbit IgG secondary polyclonal antibody, with dilution 
1:1500 (Abcam,# ab6716)for one hour. The cellswere rinsed three times with PBS.The coverslips were placed 
over slides and mounted with fluoroshieldcontaining DAPI. The slides were inspected under 
immunofluorescense microscope (Olympus BX51) with 200x magnification.Cells which only incubated with 
secondary antibody were used as negative control. 
 
Statistical analysis 
Collected results are expressed as mean  SD. Data were analyzed using ANOVAmethod followed by Tukey 
test.SPSS was used in all analyses. P<0.05was considered statistically significant. 
 
Results 
Effect of EGF and ATP treatment on NIS mRNAexpression  
    We observed that NIS mRNAisexpressed in SKBR3 and Hacat cell lines but not in MCF7. In order to 
examine the effect of EGF and ATP on NIS expression level, we treat all cell lines with ATP, EGF and the 
combination of both. 
    The levels of NIS mRNA expression, after treatment by EGF, ATP or the combination of both for 6 and 12 
hours were not significantly different from those of untreated cells (figure 1A). However, the treatment by a 
combination of ATP and EGF for 24 hours increases the level of NIS mRNA expression by 1.6 fold higher than 
that of the untreated cells (1.6241 ± 0.3, p<0.05). The treatment of ATP, EGF and the combination of both in 
Hacat cells do not increase the level of NIS mRNA expression (figure 1B).  
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Figure 1:(A)represents the effect of ATP (A), EGF (E) and a combination of ATP and EGF (AE) for 6, 12 and 
24 hours treatment on NIS mRNA expression. The combination of ATP and EGF (AE) for 24 hours treatment 
increases NIS mRNA expression of SKBR3 cell significantly when comparedto untreated cells,P<0.05.(B) NIS 
mRNA expression of Hacat cells remains unchangedfor both treated and untreated cells, P>0.05. 
 
 
Effect of EGF and ATP treatment on NIS protein expression 
 
Results of immunoflourences showed that NIS protein expressin SKBR3 (figure 2). The NIS expression in this 
cellsismostly found in cytoplasm. The treatments of EGF and the combination of both for 12 and 24 hours 
increase NIS protein expression at membrane cell(figure 2B-C). The cells which receive ATP only for 24 hours 
show a slight increase in NIS protein expression at membrane cell.  
Moreover, NIS expression can be detected in Hacat cells with and without treatments.Treatmentsof these cells 
by ATP, EGF and the combination of both induceincreasing of the expression NIS protein only in cytoplasm 
(figure 3). On the other hand, we cannot detect NIS protein expression in MCF7 cell line. This result is in 
agreement with the results of qRT-PCR.   
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Figure 2: Immunoflouresence staining using primary antibody against NIS in S
merging with DAPI staining (blue) at 200x
with ATP, EGF and the combination of both
cytoplasma and membrane after 24 hours treatment by both ATP a
 
 
Figure 3: Immunoflouresence staining using primary antibody against NIS in Hacatcell line (
merging with DAPI staining (blue) at 200x magnification
of ATP, EGF and the combination of both,
that are either treated or untreated are expressed in cytoplasm. 
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Discussion 
The expression of NIS in extra-thyroid tissueshas been reported in some previous studies, however the restuls 
were vary. These findings have been considered as potential for radioiodine therapy in extra-thyroid tumor, 
including breast cancer. A study by Tazebay, et al reported that NIS was expressed in more than 80% of 
invasive breast cancer tissues.Another study by Wapnir,et alreported that the expression was found in 76% of 
invasive breast cancer tissues. Studies by other groups reportedthat 34% out of 44 breast cancer tissues express 
NIS. They also reported that65.5% out of 23 triple negative breast cancer tissuesexpress NIS11,12,13. 
     In this study, we find that NIS mRNA and protein are expressed only in SKBR3 cells. Furthermore, the 
expression of NIS is not detectedin MCF7 cells. As previously published studieson MCF7 cells for the detection 
of NIS expression, they reported that adding retinoid acid (RA) is mandatory8,14.  Thus, it can safely be assumed 
that NIS expression in MCF7 is RA-pathway dependent. Till date, the molecular mechanisms of NIS expression 
in breast cancer are not clearly defined. So that, further studieson targeted radioiodine therapy for breast 
cancerare needed.Meanwhile, it is important to determinethe molecular breast cancer typeswhich express NIS 
as potential candidate to receive radioiodine. 
It has been established that MCF7 cell line type of breast cancer model is luminal A,with estrogen and 
progesteronereceptors positive (ER+/PR+) and HER2 receptor negative (HER2-). SKBR3 is a breast cancer cell 
line with HER2 receptor positive (HER2+),estrogen and progesterone receptors negative (ER-/PR-)9,15.A study 
by Oh et al,reported that NIS expression is not correlated with the level of hormonal receptors, such as 
ER/PR.Hormones that regulate NIS expression in breast lactating stage may not play a role in breast cancer16.  
Moreover, a study by Dohan et al reported that prolactin, oxytocin and estrogen did not induce NIS expression8. 
Theefficacy of radioiodine therapy for breast cancer will be likely dependent on the level of NIS expression at 
the membrane cell. Therefore, stimulating of the NIS expression at membrane cell will increase iodine 
uptake.Several agents are used to increase NIS expression, such as retinoic acid, hormones and proliferative 
agents2,7,17. Epidermal growth factor and ATP are classified into proliferative agent. Binding EGF with EGF 
receptor will stimulate the tyrosine kinase activityand induce cell proliferation18..Another study, by Tazebayet 
al, reported that there is a correlation between NIS expression and malignant transformation of human breast 
tissue3,4. This leads us to speculate that one of the molecular mechanism to induce cells proliferation is by EGF-
EGFR pathway to up-regulate the NIS expression.  
In this study, we observed that NIS mRNA expression and protein localization at membrane cell increases by the 
combination of ATP and EGF treatment in SKBR3 cells (Figure 2).  Treatment of ATP and EGF alone do not 
increase the level of NIS mRNA; but, increases the membrane NIS protein after 12 and 24 hours treatments. A 
Study by Jung KH et al reported that EGF treatment augmented NIS mRNA and protein expression in T47D 
cell line,which transfectedwith NIS. However, further investigation is needed to understand the molecular 
mechanism of NIS stimulation in HER2 type by EGF and ATP treatment.  
In our study, we are unable to detected NIS expression in MCF7 cells with or without treatment. These cells are 
negative or express low level of EGF receptors19. This may explain the absence of NIS expression under EGF 
induction in MCF7cells. However, EGF is able to augmented NIS expression in MCF7 cells which is 
transfectedNIS, even though the cells do not have EGF receptors.  Further studies are still required to be 
performed in order to elucidate the mechanism of NIS expression in breast cancer and the differences with NIS 
expression between the molecular subtypes of breast cancer. Additionally, NIS expression can be detected in 
Hacat cells, even though the expression is within the cytoplasm. Neither ATP nor EGF treatment will increase 
NIS expression in Hacat cells.    
 
Conclusion 
The level of NIS expression varies among the different subtypes of breast cancer cell lines. MCF7 cell line is 
representing the luminal typeof breast cancer do not express NIS as good as SKBR3cell line, which 
representsthe HER2 type. This type might be suitable to receive radioiodine therapy as those cells expressing 
NIS.A combination treatment of EGF and ATP increases the expression of NIS mRNA andprotein at 
membranein SKBR3 cells. 
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